InflammX Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.75M
- Investors
-
4
InflammX General Information
Description
Developer of an orally administered compound designed to inhibit the dysregulated inflammasome pathway of autoinflammation. The company's product offers disease modification by inhibiting the pathway by normalizing prematurely open pathological hemichannels in the cell membrane that release into the extracellular space, which is a signal for activation and release of multiple proinflammatory cytokines, helping healthcare providers to treat diabetic macular edema, macular degeneration, and chronic kidney diseases.
Contact Information
Website
www.inflammx.comCorporate Office
- 275 Bayshore Boulevard
- Unit 1607
- Tampa, FL 33606
- United States
Corporate Office
- 275 Bayshore Boulevard
- Unit 1607
- Tampa, FL 33606
- United States
InflammX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Feb-2025 | $5.75M | Completed | Clinical Trials - Phase 2 | ||
| 8. Later Stage VC | 19-Nov-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series B1) | 12-Jan-2021 | Completed | Clinical Trials - Phase 2 | |||
| 6. Secondary Transaction - Private | 01-Jan-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 20-May-2014 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B) | 24-Jul-2012 | Completed | Startup | |||
| 3. Debt - General | 06-Oct-2011 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 08-Oct-2008 | $23.2M | $23.2M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2005 | Completed | Startup |
InflammX Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series A-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
InflammX Patents
InflammX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250352508-A1 | Prevention and treatment of post-acute infection syndromes | Pending | 14-May-2024 | ||
| WO-2025240654-A1 | Prevention and treatment of post-acute infection syndromes | Pending | 14-May-2024 | ||
| CA-3212378-A1 | Compositions and methods for modulating epithelial-mesenchymal transition | Pending | 02-Mar-2021 | ||
| EP-4301381-A1 | Compositions and methods for modulating epithelial-mesenchymal transition | Pending | 02-Mar-2021 | ||
| EP-4301381-A4 | Compositions and methods for modulating epithelial-mesenchymal transition | Pending | 02-Mar-2021 | A61K31/352 |
InflammX Signals
InflammX Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ExSight Ventures | Venture Capital | Minority | ||
| Auckland UniServices | Corporate Venture Capital | Minority | ||
| Aspire NZ Seed Fund | Venture Capital | Minority | ||
| University of London | University |
InflammX FAQs
-
When was InflammX founded?
InflammX was founded in 2005.
-
Where is InflammX headquartered?
InflammX is headquartered in Tampa, FL.
-
What is the size of InflammX?
InflammX has 4 total employees.
-
What industry is InflammX in?
InflammX’s primary industry is Drug Discovery.
-
Is InflammX a private or public company?
InflammX is a Private company.
-
What is InflammX’s current revenue?
The current revenue for InflammX is .
-
How much funding has InflammX raised over time?
InflammX has raised $97.7M.
-
Who are InflammX’s investors?
ExSight Ventures, Auckland UniServices, Aspire NZ Seed Fund, and University of London have invested in InflammX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process